115 related articles for article (PubMed ID: 23807165)
1. Dysregulation of miR-106a and miR-591 confers paclitaxel resistance to ovarian cancer.
Huh JH; Kim TH; Kim K; Song JA; Jung YJ; Jeong JY; Lee MJ; Kim YK; Lee DH; An HJ
Br J Cancer; 2013 Jul; 109(2):452-61. PubMed ID: 23807165
[TBL] [Abstract][Full Text] [Related]
2. A novel targeted co-delivery nanosystem for enhanced ovarian cancer treatment via multidrug resistance reversion and mTOR-mediated signaling pathway.
Wang X; Xiong T; Cui M; Li N; Li Q; Zhu L; Duan S; Wang Y; Guo Y
J Nanobiotechnology; 2021 Dec; 19(1):444. PubMed ID: 34949180
[TBL] [Abstract][Full Text] [Related]
3. Exosomal miR-493 suppresses MAD2L1 and induces chemoresistance to intraperitoneal paclitaxel therapy in gastric cancer patients with peritoneal metastasis.
Makinoya M; Miyatani K; Matsumi Y; Sakano Y; Shimizu S; Shishido Y; Hanaki T; Kihara K; Matsunaga T; Yamamoto M; Tokuyasu N; Takano S; Sakamoto T; Hasegawa T; Saito H; Nakayama Y; Osaki M; Okada F; Fujiwara Y
Sci Rep; 2024 May; 14(1):10075. PubMed ID: 38698201
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of Drp1 orchestrates the responsiveness of breast cancer cells to paclitaxel but insignificantly relieves paclitaxel-related ovarian damage in mice.
Alalawy AI; Sakran M; Alzuaibr FM; Alotaibi MA; El-Hefnawy ME; Hazazi AY; El-Gendy SM; Aidy EA; Effat H; Ismail DF; Hessien M
Sci Rep; 2023 Dec; 13(1):22782. PubMed ID: 38129495
[TBL] [Abstract][Full Text] [Related]
5. Efficacy assessment of sustained intraperitoneal paclitaxel therapy in a murine model of ovarian cancer using bioluminescent imaging.
Vassileva V; Moriyama EH; De Souza R; Grant J; Allen CJ; Wilson BC; Piquette-Miller M
Br J Cancer; 2008 Dec; 99(12):2037-43. PubMed ID: 19034272
[TBL] [Abstract][Full Text] [Related]
6. Metronomic and single high-dose paclitaxel treatments produce distinct heterogenous chemoresistant cancer cell populations.
Mejia Peña C; Skipper TA; Hsu J; Schechter I; Ghosh D; Dawson MR
Sci Rep; 2023 Nov; 13(1):19232. PubMed ID: 37932310
[TBL] [Abstract][Full Text] [Related]
7. Bioinformatics approach combined with experimental verification reveals OAS3 gene implicated in paclitaxel resistance in head and neck cancer.
Caglar HO; Aytatli A; Barlak N; Aydin Karatas E; Tatar A; Sahin A; Karatas OF
Head Neck; 2024 May; ():. PubMed ID: 38752376
[TBL] [Abstract][Full Text] [Related]
8. circCELSR1 (hsa_circ_0063809) Contributes to Paclitaxel Resistance of Ovarian Cancer Cells by Regulating FOXR2 Expression via miR-1252.
Zhang S; Cheng J; Quan C; Wen H; Feng Z; Hu Q; Zhu J; Huang Y; Wu X
Mol Ther Nucleic Acids; 2020 Mar; 19():718-730. PubMed ID: 31945729
[TBL] [Abstract][Full Text] [Related]
9. Blood-based microRNA profiling unveils complex molecular dynamics in breast cancer.
Shahid M; Syed R; Ansari MA; Shafi G; John J
J Appl Genet; 2024 Mar; ():. PubMed ID: 38478327
[TBL] [Abstract][Full Text] [Related]
10. Novel players in the development of chemoresistance in ovarian cancer: ovarian cancer stem cells, non-coding RNA and nuclear receptors.
Alam S; Giri PK
Cancer Drug Resist; 2024; 7():6. PubMed ID: 38434767
[TBL] [Abstract][Full Text] [Related]
11. Prediction of Chemoresistance-How Preclinical Data Could Help to Modify Therapeutic Strategy in High-Grade Serous Ovarian Cancer.
Wilczyński J; Paradowska E; Wilczyńska J; Wilczyński M
Curr Oncol; 2023 Dec; 31(1):229-249. PubMed ID: 38248100
[TBL] [Abstract][Full Text] [Related]
12. Overview of miR-106a Regulatory Roles: from Cancer to Aging.
Daneshpour M; Ghadimi-Daresajini A
Bioengineering (Basel); 2023 Jul; 10(8):. PubMed ID: 37627777
[TBL] [Abstract][Full Text] [Related]
13. Deregulated miRNA clusters in ovarian cancer: Imperative implications in personalized medicine.
Kandettu A; Adiga D; Devi V; Suresh PS; Chakrabarty S; Radhakrishnan R; Kabekkodu SP
Genes Dis; 2022 Nov; 9(6):1443-1465. PubMed ID: 36157483
[TBL] [Abstract][Full Text] [Related]
14. A comprehensive survey into the role of microRNAs in ovarian cancer chemoresistance; an updated overview.
Saburi A; Kahrizi MS; Naghsh N; Etemadi H; İlhan A; Adili A; Ghoreishizadeh S; Tamjidifar R; Akbari M; Ercan G
J Ovarian Res; 2022 Jul; 15(1):81. PubMed ID: 35799305
[TBL] [Abstract][Full Text] [Related]
15. ROS and miRNA Dysregulation in Ovarian Cancer Development, Angiogenesis and Therapeutic Resistance.
Stieg DC; Wang Y; Liu LZ; Jiang BH
Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35743145
[TBL] [Abstract][Full Text] [Related]
16. Comparing the Secretomes of Chemorefractory and Chemoresistant Ovarian Cancer Cell Populations.
Lee AH; Mejia Peña C; Dawson MR
Cancers (Basel); 2022 Mar; 14(6):. PubMed ID: 35326569
[TBL] [Abstract][Full Text] [Related]
17. miRNA-122-5p in POI ovarian-derived exosomes promotes granulosa cell apoptosis by regulating BCL9.
Zhang X; Zhang R; Hao J; Huang X; Liu M; Lv M; Su C; Mu YL
Cancer Med; 2022 Jun; 11(12):2414-2426. PubMed ID: 35229987
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA-106a suppresses prostate cancer proliferation, migration and invasion by targeting tumor-derived IL-8.
Shen P; Sun G; Zhao P; Dai J; Zhang X; Zhao J; Zhu S; Chen J; Tao R; Yang J; Zeng H
Transl Cancer Res; 2020 May; 9(5):3507-3517. PubMed ID: 35117716
[TBL] [Abstract][Full Text] [Related]
19. Functional genetic variants in complement component 7 confer susceptibility to gastric cancer.
Wang S; Hu W; Xie Y; Wu H; Jia Z; Zhang Z; Zhang X
PeerJ; 2022; 10():e12816. PubMed ID: 35111412
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA and Alternative mRNA Splicing Events in Cancer Drug Response/Resistance: Potent Therapeutic Targets.
Marima R; Francies FZ; Hull R; Molefi T; Oyomno M; Khanyile R; Mbatha S; Mabongo M; Owen Bates D; Dlamini Z
Biomedicines; 2021 Dec; 9(12):. PubMed ID: 34944633
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
